Post hoc exploratory analysis of baseline data from 63 patients with moderate-severe IBS-D in an ondansetron trial: a faecal SCFA-enriched metabotype (20/63, 31.7%) was associated with more abdominal pain, urgency, stool frequency and faster gut transit.
Secondary analysisn = 63
Conley et al. The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance